Ovarian cancer: strategies for overcoming resistance to chemotherapy

By R. Agarwal, S. Kaye. Nature Reviews. Cancer, 2003

1,178 citations recorded by the source corpus.

Subfields: Genetics, Oncology, Reproductive Medicine

View Paper: https://www.semanticscholar.org/paper/30c697227b53a24a717c91933f85bdd21b8a524b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Shaloam Dasari
2. P. Tchounwou
3. Alan Ashworth
4. Andrew Tutt
5. Sameer Quazi
6. Jan H. M. Schellens
7. M. Lutolf

In Oncology

1. Alan Ashworth
2. Shaloam Dasari
3. P. Tchounwou
4. J. D. de Bono
5. M. Lutolf
6. C. Lord

In Reproductive Medicine

1. Shaloam Dasari
2. P. Tchounwou
3. Alan Ashworth

Citations in the corpus

• Apoptosis and Molecular Targeting Therapy in Cancer (2014, background): “Bcl-2 members are localized in the mitochondria and have either proapoptotic (Bax, Bak, Bid, and Bim) or antiapoptotic (Bcl-2, Bcl-xL, and Bcl-W) functions [8, 83, 84].”
• Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. (2010, background): “At this late disease stage, chemotherapy resistance occurs, for reasons as yet unknown [39].”
• Nanoparticles for Cancer Therapy: Current Progress and Challenges (2021, background): “Overexpression of P-gp has been linked with inadequate treatment response, especially in breast cancer [138] and ovarian cancer [139].”
• Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. (2010, background): “resistance is clinically defined as disease progression within 6 months of prior platinum therapy.(3) Ac-”
• Cisplatin in cancer therapy: molecular mechanisms of action (2014, positive): “Patients with recurrent ovarian cancer ultimately develop resistance to chemotherapy and eventually succumb to the disease (Agarwal and Kaye, 2003).”
• Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance (2020, background): “In addition, high expression of P-gp has been associated with poor treatment-response in many tumors, such as breast (Chintamani et al., 2005) and ovarian cancer (Agarwal and Kaye, 2003).”